Recreational Marijuana Laws Tied to Increase in Workplace Injuries
By Lori Solomon HealthDay Reporter
FRIDAY, March 1, 2024 -- Recreational marijuana laws (RMLs) that allow recreational marijuana sales are associated with an increase in workplace injuries among young adults, according to a research letter published online Feb. 23 in JAMA Health Forum.
Ling Li, Ph.D., from University of Wisconsin-Parkside in Somers, and colleagues evaluated the association between RML adoption and workplace injuries in younger workers (aged 20 to 34 years). The analysis included workplace injury data from the Bureau of Labor Statistics Survey of Occupational Injuries and Illnesses.
The researchers found that when controlling for marijuana policies, state dummies, and year dummies, RML adoption was associated with a statistically significant 12.9 percent increase (β, 0.121) in workplace injuries per 100 full-time workers. In fully adjusted models, the estimated increase was 9.6 percent (β, 0.092). RML adoption that allowed for recreational sales was associated with an 8.4 percent increase (β, 0.081) in the fully adjusted specification. Recreational sales (e.g., dispensaries) were associated with an 11.9 percent increase (β, 0.112) in workplace injuries per 100 full-time workers and a 10.0 percent increase (β, 0.095) in injuries per 100 persons in the fully adjusted regressions. There was no association with injuries for RMLs that did not allow sales.
"Our findings are consistent with the hypothesis that recreational marijuana impedes cognitive function and care among younger workers," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.